Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: required (1000), wanted (88), hunted (8)

Pembrolizumab Ver 1 skin

Description: Chemotherapy Protocol SKIN CANCER Pembrolizumab Pembrolizumab is currently available on a compassionate use basis only – not yet licensed in the UK
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/SkinPembrolizumabVer1.pdf

Nivolumab Ver 1.1 skin

Description: Chemotherapy Protocol SKIN CANCER Nivolumab This regimen may require funding. Regimen Skin – Nivolumab Indication The treatment of advanced (unresectable or metastatic
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/NivolumabVer1.1.pdf

Ipilimumab-Nivolumab

Description: Chemotherapy Protocol SKIN CANCER IPILIMUMAB (3mg/kg)-NIVOLUMAB (1mg/kg) Regimen • Skin – Ipilimumab (3mg/kg)-Nivolumab (1mg/kg) Indication • Ipilimumab in
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Ipilimumab-Nivolumab.pdf

Hydration Pilots application and support pack process

Description: January Classification: Official Hydration Pilots: Application support pack & process Hydration Pilots: application support pack and process 1.0 Aim The NH
Url: /Media/Southampton-Clinical-Research/Grants/Download/Hydration-Pilots-application-and-support-pack-process.docx

Ipilimumab-Nivolumab Ver1

Description: Chemotherapy Protocol MESOTHELIOMA IPILIMUMAB-NIVOLUMAB Regimen • Mesothelioma – Ipilimumab-Nivolumab Indication • Nivolumab in combination with ipilimumab is indicated for the first-line
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Mesothelioma/Ipilimumab-Nivolumab-Ver1.pdf

Electrophysiology study - patient information

Description: Information about having an electrophysiology study
Url: /Media/UHS-website-2019/Patientinformation/Heartandlungs/Electrophysiologystudy-723-PIL.pdf

Supplier representative procedure

Description: Procurement and supply chain and the commercial development team appreciate the role that companies play to assist the Trust in providing
Url: /Media/UHS-website-2019/Docs/Policies/Supplier-representative-procedure.pdf

Cetuximab-Irinotecan (21day)

Description: Chemotherapy Protocol COLORECTAL CANCER CETUXIMAB-IRINOTECAN (21 day) This regimen may require funding Regimen • Colorectal Cancer–Cetuximab-Irinotecan (21 day) Indication
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Colorectal/Cetuximab-Irinotecan.pdf

Atezolizumab-Paclitaxel Albumin Bound

Description: Chemotherapy Protocol BREAST CANCER Atezolizumab-Paclitaxel Albumin Bound Regimen • Breast – Atezolizumab-Paclitaxel Albumin Bound Indication • Atezolizumab in combination with paclitaxel albumin
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Atezolizumab-Paclitaxel-Albumin-Bound.pdf

G29 Guideline on completion application and study assessment v1 14-10-20...

Description: Guideline on completion of the Sponsorship Application and Study Assessment Introduction According to the UK Policy Framework for Health and Social
Url: /Media/Southampton-Clinical-Research/Downloads/G29-Guideline-on-completion-application-and-study-assessment-v1-14-10-20....pdf

531 to 540 of 571

Previous … 52 53 54 55 56 … Next